The Anthropic IPO Could Make These 5 AI Stocks Unexpected Winners

Anthropic filed confidentially for a U.S. IPO after a $65 billion Series H round valued the company at nearly $1 trillion, highlighting massive future AI infrastructure demand. The article argues that Celestica, Credo, Astera Labs, Coherent, and Marvell are positioned to benefit from Anthropic’s more than $100 billion AWS commitment and 10 GW of contracted compute capacity. Marvell also jumped 33% in one session, adding about $56 billion in market value after Jensen Huang called it a potential trillion-dollar company.

Analysis

The real trade is not Anthropic equity; it is the capex multiplier embedded in the ecosystem that has to scale before the IPO process can credibly re-rate the company. Once a frontier model supplier becomes a public-market story, the market will start underwriting a multi-quarter acceleration in training and inference capacity, which pulls forward spend on racks, optics, interconnect, and custom silicon before the IPO itself is even priced. That creates a second-order winner set: suppliers with real deployment bottlenecks and long qualification cycles should capture the earliest and stickiest incremental dollars.

The most asymmetric beneficiaries are the picks-and-shovels names with exposure to the physical layer of AI clusters, but the market is already halfway there on the obvious AI hardware proxies. The less appreciated angle is that hyperscaler contract commitments are effectively de-risking demand for a broader bill of materials, which should narrow revenue uncertainty for vendors that sit one layer below the marquee accelerator names. That favors companies with secular share gains in cluster assembly and connectivity over pure semiconductor beta, because the former benefit even if customers diversify away from Nvidia-centric architectures.

The main risk is timing: IPO headlines are near-term bullish, but actual revenue recognition from infrastructure buildouts tends to lag by quarters, and sentiment can outrun order flow. If the IPO slips, is downsized, or the market decides Anthropic is already fully funded, the narrative can unwind quickly in the fastest-rerating names, especially those that just spiked on the theme. The other underappreciated risk is that investors are crowding into the same AI capex basket, so any disappointment in hyperscaler spending guidance could trigger a sharp de-grossing across the complex.

The contrarian view is that the market may be underestimating how much of this demand ends up being monopolized by a few infrastructure vendors with real design-in leverage, while overestimating the durability of the more promotional “AI beneficiary” trade. Marvell looks the most crowded on the article’s framing: if the market is already capitalizing future XPU wins, upside may be more linear than explosive from here, while operating leverage and execution risk remain. A better expression is to own the enablers with more direct order conversion and pair them against names where the valuation already implies flawless AI expansion.

Key Decisions for Investors

• Go long CLS into the next 4-8 weeks as the cleanest cluster-assembly beneficiary; use a 10-15% stop because the name should outperform on any confirmed hyperscaler capex update, but can de-rate fast if AI spending is delayed.
• Buy ALAB on pullbacks and hold 3-6 months; the risk/reward is attractive because connectivity silicon tends to be a multi-generation design-in winner, but position size should reflect that the market may already price some of the AI fabric upside.
• Pair trade long CLS / short MRVL for 1-2 quarters: CLS has more direct sensitivity to physical deployment, while MRVL’s recent rerating leaves more downside if the market reclassifies the Anthropic story as already reflected in consensus.
• For higher-conviction event risk, consider call spreads on COHR over 2-4 months; the setup benefits from continued optics demand, but spreads cap premium bleed if the broader AI trade pauses.
• Avoid chasing AMZN and GOOGL on this headline alone; they are structural beneficiaries, but the incremental upside from the Anthropic IPO narrative is likely smaller than for supply-chain pure plays.